SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as its strong Q4 earnings, profitability, and new share buyback authorization have ironically led to a significant stock decline, sparking widespread frustration among investors. The community is fiercely debating whether ongoing stock-based compensation and dilution are overshadowing the company's growth in subscriptions and long-term potential in AI/AR smartglasses.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining attention as recent FDA action against "copycat" GLP-1 compounded drugs highlights the value of legitimate innovation, while strong results from Eli Lilly intensify pressure on competitors like Novo Nordisk, who the community believes urgently need Viking's "best-in-class" VK2735 asset to remain competitive in the rapidly expanding obesity market.

Dynatrace, Inc. engages in the advancing observability for today’s digital businesses, helping to transform the complexity of modern digital ecosystems into powerful business assets. By leveraging AI-powered insights, Dynatrace enables organizations to analyze, automate, and innovate faster to drive their business forward. The company was founded by Bernd Greifeneder in 2005 and is headquartered in Boston, MA.

Dynatrace Inc

Dynatrace is trending following its strong Q3 fiscal year 2026 earnings report, which surpassed expectations across key metrics and included the authorization of a $1 billion share repurchase program. This positive financial performance and commitment to shareholder returns are fueling optimistic discussions among the community, despite some recent analyst target adjustments.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health ($OSCR) is trending after the House passed a bill to extend ACA subsidies, sparking intense community debate on its potential for future growth and profitability, with investors keenly focused on the upcoming earnings report and crucial 2026 guidance amidst broader healthcare sector sentiment.

Investment Managers Series Trust II - Tradr 2X Long CRML Daily ETF

Tradr 2X Long CRML Daily ETF

Tradr's recently launched 2X leveraged ETF, $CRMX, tracking Critical Metals ($CRML) and its rare earth projects, is actively discussed as traders debate its actual leverage performance and monitor for a potential breakout from quiet accumulation on increased volume. Many are closely watching its tight consolidation and small float dynamics for an upward move.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork (UPWK) is trending sharply lower after providing a weaker-than-expected outlook, despite reporting a beat on its recent earnings. The community is actively debating if the platform is becoming obsolete due to advancing AI technology, while some view the sell-off as an overreaction and a buying opportunity.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending after the abrupt departures of its CFO and General Counsel amid an ongoing accounting review, an SEC investigation, and disclosures of material weaknesses in internal controls and a lowered fiscal outlook. The community is sharply divided, with many voicing deep concerns about potential fraud and a continued decline, while others are aggressively buying the significant dip, anticipating an oversold rebound.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending due to the FDA's Complete Response Letter for its Hunter syndrome gene therapy, RGX-121, citing concerns over trial design, including natural history controls and the surrogate endpoint. This decision has ignited community debate, with many investors anticipating a substantial stock drop and others expressing frustration over the FDA's stringent approach to rare disease gene therapies.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is gaining significant traction following bullish analyst initiations, with firms like Cantor Fitzgerald labeling it the "Amazon of Africa" and setting an $18 price target. This momentum, combined with strong Q4 sales and expectations for imminent profitability, is fueling community excitement around its long-term potential in Africa's rapidly expanding e-commerce market.

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA.

Tectonic Therapeutic Inc.

Tectonic Therapeutic is garnering significant attention after announcing positive Phase 1b trial data for its TX45 asset, leading analysts to issue lofty price targets. The community is actively discussing the drug's differentiated mechanism in addressing a large unmet medical need, fueling speculation of a short squeeze following past market overreactions to competitor drug failures.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock...

Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Rises By 28.6%

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling...

Gain Therapeutics Shares Early Phase 1b Data: GT-02287 Shows UPDRS Gains, Key PD Biomarker Drop

Gain Therapeutics (NASDAQ:GANX) highlighted early clinical and biomarker findings from the first 90 days of its ongoing Phase 1b open-label study evaluating GT-02287 in people with Parkinson's...

Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven brokerages that are currently covering the firm, Marketbeat reports. One...

Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) saw a significant growth in short interest in December. As of December 15th, there was short interest totaling 2,073,310 shares, a growth of...

Gain Therapeutics (GANX) Upgraded to Buy: Here's Why

Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated a "buy" rating and set a $8.00 price target on shares of Gain Therapeutics in a research report on Friday...

Is Enhabit, Inc. (EHAB) Stock Outpacing Its Medical Peers This Year?

Here is how Enhabit (EHAB) and Gain Therapeutics, Inc. (GANX) have performed compared to their sector so far this year.

Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy

Does Gain Therapeutics, Inc. (GANX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) have received an average rating of "Moderate Buy" from the eight brokerages that are currently covering the company, Marketbeat...

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never targeted before. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Gain Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$1.79
Prev Close	$1.75
Open	$1.78
Dividend Yield	0.00%
50-Day Moving Average	$2.77
Beta	1.12
Avg. Volume	1.09M
PE Ratio	-2.74

52-Week High	$4.34
52-Week Low	$1.41
Market Capitalization	$67.31M
EPS (Annual)	-$0.892
Price to Book	10.65
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

GANX
Gain Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GANX News

GANXGain Therapeutics Inc